APUS Shariah Compliance
Screening Methodology: AAOIFI
UNLOCK FOR FREE
Last Updated: November 24, 2025
Report Source: 2025 3rd Quarter Report
Apimeds Pharmaceuticals US Inc. Stock Analysis APUS
United States Health Care Nano Cap Report: Apimeds Pharmaceuticals US, Inc. is a clinical stage biopharmaceutical company that engages in the development of Apitox, an intradermally administered bee venom-based toxin. The company is headquartered in Matawan, New Jersey and currently employs 2 full-time employees. The company went IPO on 2025-05-09. The firm is engaged in developing Apitox, an intradermally administered bee venom-based toxin. The company is focused on developing Apitox in the treatment of inflammatory conditions in the United States, specifically osteoarthritis and multiple sclerosis. Its subsidiary, MindWave Innovations Inc, is a provider of institutional digital asset treasury (DAT) solutions.
Read More Apimeds Pharmaceuticals US Inc (APUS) Chart
Key Statistics of Apimeds Pharmaceuticals US Inc (APUS)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$1.64Volume
129.79KP/E Ratio (TTM)
-52 Week Range
Market Cap
23.27MAvg. Volume
96.06KDividend Yield
-Financial Metrics & Statements of Apimeds Pharmaceuticals US Inc (APUS)
FAQ's for Apimeds Pharmaceuticals US Inc (APUS)
- According to Musaffa’s Shariah screening methodology, Apimeds Pharmaceuticals US Inc (APUS) is currently classified as NOT HALAL as of November 2025. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
Alternate Halal Stocks for Apimeds Pharmaceuticals US Inc (APUS)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
